Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa

International Journal of Tuberculosis and Lung Disease

Volumn 6, Issue 4, 2002, Pages 356-361

  McIlleron, H ^a   Wash, P ^a   Burger, A ^a   Folb, P ^a   Smith, P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Bioavailability; Formulation; Patients; Rifampicin

Indexed keywords

ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFACAP; RIFAMPICIN; ROLAB RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SOUTH AFRICA; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY CONTROL; RIFAMPIN; SOUTH AFRICA; TUBERCULOSIS, PULMONARY;

EID: 0036201298     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Official IUATLD/WHO joint statement. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications
2. Rifampicin bioavailability: A review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption
3. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability
4. Rifampicin raw material characteristics and their effect on bioavailability
5. Estimate of the global market for rifampicin-containing fixed-dose combination tablets
6. Low anti-tuberculosis drug concentrations in patients with AIDS
7. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhoea
8. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients
9. Using therapeutic drug monitoring to dose the antimycobacterial drugs
10. An HPLC method for the simultaneous determination of rifampicin, isoniazid and pyrazinamide in serum
11. Improved GLC determination of ethambutol
12. Fixed-dose combination formulations for tuberculosis treatment